Serotonin (5-hydroxytryptamine or 5-HT) is thought to regulate neurodevelopmental processes through maternal-fetal interactions that have long-term mental health implications. It is thought that beyond fetal 5-HT neurons there are significant maternal contributions to fetal 5-HT during pregnancy 1,2 but this has not been tested empirically. To examine putative central and peripheral sources of embryonic brain 5-HT, we used Pet1 2/2 (also called Fev) mice in which most dorsal raphe neurons lack 5-HT 3 . We detected previously unknown differences in accumulation of 5-HT between the forebrain and hindbrain during early and late fetal stages, through an exogenous source of 5-HT which is not of maternal origin. Using additional genetic strategies, a new technology for studying placental biology ex vivo and direct manipulation of placental neosynthesis, we investigated the nature of this exogenous source. We uncovered a placental 5-HT synthetic pathway from a maternal tryptophan precursor in both mice and humans. This study reveals a new, direct role for placental metabolic pathways in modulating fetal brain development and indicates that maternal-placental-fetal interactions could underlie the pronounced impact of 5-HT on long-lasting mental health outcomes.
Serotonin (5-hydroxytryptamine or 5-HT) is thought to regulate neurodevelopmental processes through maternal-fetal interactions that have long-term mental health implications. It is thought that beyond fetal 5-HT neurons there are significant maternal contributions to fetal 5-HT during pregnancy 1, 2 but this has not been tested empirically. To examine putative central and peripheral sources of embryonic brain 5-HT, we used Pet1 2/2 (also called Fev) mice in which most dorsal raphe neurons lack 5-HT 3 . We detected previously unknown differences in accumulation of 5-HT between the forebrain and hindbrain during early and late fetal stages, through an exogenous source of 5-HT which is not of maternal origin. Using additional genetic strategies, a new technology for studying placental biology ex vivo and direct manipulation of placental neosynthesis, we investigated the nature of this exogenous source. We uncovered a placental 5-HT synthetic pathway from a maternal tryptophan precursor in both mice and humans. This study reveals a new, direct role for placental metabolic pathways in modulating fetal brain development and indicates that maternal-placental-fetal interactions could underlie the pronounced impact of 5-HT on long-lasting mental health outcomes.
Fetal 5-HT dysfunction is implicated in developmental programming by altering brain circuit formation 4 , which later translates into abnormal adult behaviours 5, 6 . In humans, risk alleles in genes involved in 5-HT function combine with early adverse experiences during development to affect adult-onset mental illnesses 7 . Furthermore, polymorphisms in the 5-HT transporter (SLC6A4, which encodes SERT) and 5-HT receptors, which are expressed early in brain development 8 , are associated with neurodevelopmental disorders such as autism spectrum disorder and schizophrenia 9, 10 . A puzzling issue regarding the role of 5-HT in fetal brain development is that receptors, transporters and degrading enzymes for 5-HT often appear before the development of 5-HT innervation 11 itself, suggesting the existence of an exogenous source of 5-HT at early stages of development. The most biologically influential source of exogenous 5-HT is claimed to be maternal 1,2 but there is a lack of experimental data to support such a mechanism of developmental programming.
Analysis of fetal Pet1 2/2 mice provides an opportunity to assess potential extra-embryonic sources of 5-HT, as only ,30% of dorsal raphe 5-HT neurons can be detected in null mice, which also express low levels of tryptophan hydrolase 2 (TPH2), aromatic l-amino acid decarboxylase (AADC; also called dopa decarboxylase, Ddc), SERT and other markers of the serotonergic phenotype 3 . To assess whether dorsal raphe neurons are also the sole source of brain 5-HT during development, we compared the concentration of 5-HT in embryonic brains collected from Pet1 2/2 and wild-type littermates from embryonic day (E) 10.5, the onset of 5-HT synthesis in dorsal raphe neurons, to E17.5, when 5-HT axons are fully deployed throughout the forebrain. High-performance liquid chromatography (HPLC) was used to measure the concentration of 5-HT in the mid/hindbrain region (termed 'hindbrain'), which contains 5-HT cell bodies and proximal axons, and in the forebrain, which contains only distal 5-HT axons 12, 13 . Consistent with dorsal raphe neurons providing the main source of 5-HT in the hindbrain, the 5-HT concentration was lower in Pet1 2/2 hindbrains than in those of wild-type mice at every age tested ( Fig. 1a ). Notably, in the Pet1 2/2 forebrain, 5-HT levels were statistically indistinguishable from wild type at E10.5 to E15.5; however, large differences emerged at E16.5 (Fig. 1b ). This is consistent with dorsal raphe axons being the major source of forebrain 5-HT at this and later ages but not earlier ( Supplementary Fig. 2 and ref. 3). Remarkably, even before the arrival of 5-HT axons in the ventral forebrain (E10.5-E12.5), low levels of 5-HT were detected ( Fig. 1b) . Normally, over the next three embryonic days, progressively more 5-HT axons grow into the forebrain 13 ( Fig. 1c-e ). In the Pet1 2/2 forebrain, however, there is a marked reduction in 5-HT axon density compared to wild type ( Fig. 1c -i), even though total tissue 5-HT concentrations are comparable. The density and distribution of thalamocortical axons, which also express SERT and can take up 5-HT 14 , are similar in Pet1 2/2 and wild-type mice ( Fig. 1c, f) . These results reveal a complex regulation of 5-HT in the fetal brain, with dorsal raphe serotonergic neurons and axons representing the major source of 5-HT in the hindbrain and at later embryonic stages in the forebrain but not the main source of 5-HT in the early developing forebrain.
The greater decrease in total tissue 5-HT concentration in the hindbrain than in the forebrain in Pet1 2/2 mice suggests a differential contribution of non-dorsal-raphe sources in these regions. Alternatively, because 5-HT degradation enzyme (monoamine oxydase A; MAO-A) activity is higher in the hindbrain than in the forebrain at early stages of development 15 , a differential degradation of 5-HT across the two brain regions may account for the difference. Consistent with this latter possibility, 5-hydroxyindoleacetic acid (5-HIAA) concentration in the E14.5 sMaoa 2/2 mouse (which lacks MAOA enzymatic activity and cannot efficiently degrade 5-HT 16 ) were decreased 3.4-fold in the forebrain, but 6.1-fold in the hindbrain compared to wild type littermates ( Supplementary Fig. 3 ). In contrast, at E16.5, 5-HIAA concentrations were decreased to a similar extent in the sMaoa 2/2 forebrain and hindbrain (3.6-and 3.1-fold respectively). A downregulation of MAOA activity in the Pet1 2/2 forebrain before E16.5 could explain the normal concentrations of 5-HT measured in the region. To test this possibility, we quantified MAOA activity in the forebrain at E14.5 and showed that it was not different in Pet1 2/2 , Pet1 1/2 and Pet1 1/1 forebrains (Supplementary Table 2 ). Furthermore, 5-HIAA concentrations were not different in the Pet1 2/2 and Pet1 1/1 forebrains at E12.5 and E14.5 ( Supplementary Fig. 3c ). The data demonstrate that MAO-A activity is not downregulated in the Pet1 2/2 forebrain.
The non-dorsal-raphe origin of 5-HT in the early fetal forebrain could arise from several sources. Because adult forebrain catecholaminergic and dopaminergic neurons express the AADC enzyme, these cells can ectopically synthesize 5-HT, albeit after administration of large doses of the precursor 5-HTP 17 . We tested the possibility that embryonic AADC-expressing neurons could ectopically produce 5-HT in the early Pet1 2/2 forebrain. Consistent with measures of unaltered dopamine concentration ( Supplementary Fig. 1 ), AADC immunostaining revealed normal catecholaminergic and dopaminergic neuron and axon density in the Pet1 2/2 forebrain ( Fig. 1j ). Furthermore, catecholaminergic neurons present in the Pet1 2/2 hypothalamus do not exhibit ectopic 5-HTP or 5-HT immunoreactivity ( Fig. 1k ), consistent with there being no local cellular source of 5-HT in the Pet1 2/2 forebrain.
In the developing forebrain, E10.5-E15.5 is the period of pronounced neurogenesis and axon growth. As 5-HT modulates both processes 4,10 , it is essential that its availability be regulated during this time. It is remarkable, therefore, that over this time period, even in the absence of 5-HT axons, the concentration of 5-HT in the Pet1 2/2 forebrain is normal. Possible exogenous sources include the embryonic gut, the maternal blood through the placenta, or the placenta itself. We ruled out the embryonic gut as a source because expression of the 5-HT biosynthetic enzyme tryptophan hydroxylase (TPH1), which provides blood 5-HT, begins late (E15.5) in fetal enterochromaffin cells 1, 18 . To test the possibility that maternal 5-HT is transferred to the fetal brain, we examined brains from fetuses of Sert knockout (Sert 2/2 ) dams; total blood and platelets in these dams contain virtually no 5-HT 19 . This absence of blood 5-HT is attributed to a failure of uptake by platelets, to rapid degradation of the remaining free plasma 5-HT in the liver and to compensatory uptake by other transporters in the gut 19 . Despite this, the concentration of 5-HT is not different in the forebrain of Sert 1/2 E12.5 embryos from Sert 2/2 or wild-type dams (Supplementary Table 1 ), indicating that maternal blood 5-HT is not the main source of fetal blood and forebrain 5-HT at early stages of development.
We considered the alternative hypothesis that the essential amino acid tryptophan, originating from the pregnant dam, would be converted to 5-HT in the placenta and delivered to the fetal circulation. Injection of tryptophan in pregnant dams increases 5-HT concentration in the fetal brain 20 but the precise location of the synthetic conversion has never been identified. Quantitative RT-PCR of placental tissue detected transcripts of Tph1 and Aadc, but not Pet1 ( Supplementary  Fig. 4a ). Immunocytochemistry confirmed that TPH1 and AADC proteins are expressed in the syncytiotrophoblastic cell layer of the placenta at E10.5-E14.5 ( Fig. 2c-h and Supplementary Fig. 4e -j). The placenta thus has the necessary machinery to synthesize 5-HT. We tested for placental 5-HT neosynthesis and showed that both 5-HTP and 5-HT neosyntheses occur in placenta and fetal hindbrain extracts incubated with tryptophan ( Fig. 2a ) as early as E10.5 (Supplementary Fig. 4b ). Placental 5-HT synthesis capacity was greater at E14.5 than at E18.5, whereas the converse was true in the hindbrain, consistent with changes in Tph1 transcript expression (data not shown). The capacity for placental 5-HT synthesis at E14.5 was not affected by the absence of embryonic Pet1 gene expression (Supplementary Fig. 4c ). This synthetic capacity is not unique to mice, as human placental fetal villi at 11 weeks of gestation showed robust 5-HT neo-synthesis ( Fig. 2b ), indicating that a placental source of 5-HT is important for human fetal development.
Although not providing conclusive proof, these data are consistent with the possibility that neosynthesis and transport of 5-HT from a maternal tryptophan precursor occurs in an intact placenta. We addressed this with two strategies. First, we developed a novel ex vivo technology for regulating placental organ perfusion, thus allowing the presentation of maternal precursor and the collection of fetal perfusate in intact, live murine placentas ( Fig. 2i ). Within 15 min of tryptophan injection through the maternal uterine artery, there was a large accumulation of newly synthesized 5-HT that passes through the fetal placental circulation (Fig. 2j ), demonstrating that the live placenta is able to convert tryptophan to 5-HT and release the neurotransmitter into the fetal circulation. In contrast, when 5-HT (1.5 nM) was injected into the uterine artery, only 0.32 6 0.16% of the maternal free 5-HT was transferred to the fetal umbilical vein during a 30 min perfusion forebrain of Pet1 2/2 and wild type embryos from E10.5 to E17.5. a, 5-HT concentration in the Pet1 2/2 (KO) hindbrain is significantly lower than in wildtype (WT) littermates at every age tested. b, In contrast, 5-HT concentrations in the Pet1 2/2 forebrain are not significantly different from wild-type littermates from E10.5 to E15.5 but become significantly lower at E16.5 and E17.5 (n $ 6 embryos per genotype per age; *, P , 0.005; one-way analysis of variance (ANOVA); data are presented as means 6 s.e.m. 
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period. In a second strategy, we specifically blocked placental TPH1 enzyme activity by microinjecting small volumes of the TPH inhibitor p-chlorophenyalanine (PCPA) directly into the labyrinth zone of E14.5 placentas in utero ( Fig. 3a ). To minimize nonspecific effects due to diffusion of the drug into the maternal and fetal blood compartments, placental and fetal brain tissues were collected after a short 30-min period of drug exposure. This pharmacological manipulation reduced 5-HT levels in the placenta but did not reduce 5-HT in the fetal hindbrain, indicating that exposure to PCPA was too short to inhibit TPH2 activity in dorsal raphe serotonergic neurons (Fig. 3b ). Nevertheless, the brief exposure to PCPA resulted in a significant decrease in fetal forebrain 5-HT levels (Fig. 3b ). The data demonstrate that an exogenous source of 5-HT produced in the placenta is required to maintain normal levels of forebrain 5-HT during early stages of forebrain development ( Supplementary Fig. 5 ).
The concept that 5-HT from maternal blood could be transferred to the fetal circulation after crossing the placenta is widely accepted 1,2 but direct or indirect transfer of the molecule has never been demonstrated. Although uptake of exogenous 5-HT by syncytiotrophoblasts in the human and mouse placenta was demonstrated in vitro 2,21 , the concomitant high level of Maoa expression suggests that the placenta would prevent the vasoconstrictive effect of any free maternal blood 5-HT (a small fraction of total blood 5-HT 19 ) rather than transfer it to the fetus 21 . This potentially lethal bioactivity and the quasi-absence of maternal blood 5-HT transfer to the fetus has been demonstrated previously 20, 22 and also in this study. A recent study concluded that maternal 5-HT is crucial for early fetal development (before E11 1 ) based on abnormal phenotypes that emerge in embryos of Tph1 2/2 pregnant dams. Indirect effects of the Tph1 2/2 maternal mutation, however, cannot be excluded as Tph1 2/2 mice are diabetic 23 , a pathological condition that affects fetal development independently of a direct maternal 5-HT effect 24 . Although the importance of a maternal source of 5-HT before and during placentation remains an open question, our results provide the first direct evidence for maternal influences on fetal brain development through a precursor that is metabolized directly by the placenta. Given our demonstration of synthetic capability 
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in the early human placenta, it will be clinically important to define the specific time period during human pregnancy for this placental influence on brain development. The present results also emphasize the need to examine fetal and placental tryptophan availability. Mutations in tryptophan 2,3-dioxygenase degrading enzymes (TDO1 and TDO2, which are expressed in the placenta 25 ) affect neurogenesis, produce anxiety-related behaviour in mice 26 and are associated with increased risks of schizophrenia, bipolar disorder and autism 27, 28 . Our results provide a mechanism through which alterations of tryptophan metabolic pathways in the placenta would affect placental 5-HT synthesis and fetal forebrain development.
Our study provides a new framework for understanding the complexity of maternal-fetal relationships that can influence brain structure and function. We focused on the 5-HT system and showed that there is a progressive switch from an early dependence on an exogenous (placental) source of 5-HT to a later endogenous brain source (Fig. 3c) . The exogenous source of 5-HT is provided to the forebrain during developmental epochs that include cortical neurogenesis, migration and initial axon targeting 10 . These events can be negatively affected by disrupting 5-HT signalling: we demonstrated that a forebrainspecific disruption of 5-HT signalling in vivo affects axon guidance, leading to abnormal thalamocortical axon trajectories 4 . This phase in the mouse corresponds to the first and early second trimesters in the human: prenatal periods that are associated with greater risk for mental illnesses due to maternal perturbations 29, 30 . Thus, translation of our findings to those corresponding periods in the human will be of significant clinical relevance.
METHODS SUMMARY
Animals and reagents. Timed-pregnant CD-1 mice were purchased from the Charles River Laboratory. Plug date was considered E0.5 and the age of individual embryos was confirmed by measuring the crown-rump length and checking for developmental landmarks such as digits and eye formation. Pet1 (ref.
3) knockout (2/2), heterozygotes (1/2)andwild-type(1/1) littermate embryos were generated by crossing Pet1 1/2 males and females. Sert 1/2 embryos were obtained by crossing Sert 2/2 females 19 with wild-type C57BL/6 males. The Pet1 and Sert knockout lines have been backcrossed on the C57Bl/6J background for .10 generations. The Maoa spontaneous knockout mouse (sMaoa KO) was described earlier 16 . All procedures using mice were approved by the Institutional Animal Care and Use Committee at University of Southern California and conformed to NIH guidelines. Unless otherwise noted, all reagents and antibodies were purchased from Sigma. Protocols for HPLC, tissue staining, in vitro 5-HT synthesis assays, MAOA enzymatic activity assays, in vivo synthesis inhibition assays and ex vivo placental perfusions are described in Methods. Human placenta samples. Normal human placental villi samples were obtained from women undergoing elective pregnancy terminations at the Reproductive Options Clinic at the Los Angeles County (LAC) and University of Southern California (USC) Medical Center. For the purposes of this study, the tissue was carefully dissected by the pathologist and immediately flash-frozen in liquid nitrogen. No patient characteristics other than gestational age were recorded. The University of Southern California Health Science Campus Institutional Review Board approved this study.
METHODS
Animals and reagents. Timed-pregnant CD-1 mice were purchased from the Charles River Laboratory. Plug date was considered E0.5 and the age of individual embryos was confirmed by measuring the crown-rump length and checking for developmental landmarks such as digits and eye formation. Pet1 (ref. 3) knockout (2/2), heterozygotes (1/2) and wild-type (1/1) littermate embryos were generated by crossing Pet1 1/2 males and females. Sert 1/2 embryos were obtained by crossing Sert 2/2 females 19 with wild-type C57BL/6 males. The Pet1 and Sert knockout lines have been backcrossed on the C57Bl/6J background for .10 generations. The Maoa spontaneous knockout mouse (sMaoa KO) was described earlier 16 . All procedures using mice were approved by the Institutional Animal Care and Use Committee at University of Southern California and conformed to NIH guidelines. Unless otherwise noted, all reagents and antibodies were purchased from Sigma. Human placenta samples. Normal human placental villi samples were obtained from women undergoing elective pregnancy terminations at the Reproductive Options Clinic at the Los Angeles County (LAC) and University of Southern California (USC) Medical Center. For the purposes of this study, the tissue was carefully dissected by the pathologist and immediately flash-frozen in liquid nitrogen. No patient characteristics other than gestational age were recorded. The University of Southern California Health Science Campus Institutional Review Board approved this study. HPLC measures. Hindbrains and forebrains were homogenized, using a tissue dismembrator, in 100-750 ml of 0.1 M trichloroacetic acid TCA, which contains 10 22 M sodium acetate, 10 24 M EDTA, 5 ngml 21 isoproterenol (as internal standard) and 10.5% methanol (pH 3.8). Samples were spun at 10,000g for 20 min. The supernatant was removed and stored at 280 uC. The pellet was used for protein analysis; total protein concentrations were determined using the BCA Protein Assay Kit (Pierce Chemical Company). The supernatant was then thawed and spun for 20 min. The concentration of biogenic amines in each sample was determined by a specific HPLC assay using an Antec Decade II (oxidation, 0.5 V) electrochemical detector operated at 33 uC. 20 ml samples of supernatant were injected using a Water 7171 autosampler onto a PhenomenexNucleosil (5 u, 100 A) C18 HPLC column (150 3 4.60 mm). Biogenic amines were eluted with a mobile phase consisting of 89.5% 100 mM TCA, 10 mM sodium acetate, 0.1 mM EDTA and 10.5% methanol (pH 3.8). Solvent was delivered at 0.6 mlmin 21 using a Waters 515 HPLC pump. Using this HPLC solvent, the biogenic amines eluted in the following order: noradrenaline, adrenaline, DOPAC, dopamine, 5-HIAA, HVA, 5-HT and 3-MT. HPLC control and data acquisition were managed by Millennium 32 software. Statistical analysis. Measures in Pet1 2/2 and wild-type littermate embryos (n $ 6 per genotype) are presented as mean 6 s.e.m. Statistical comparison of measures between genotypes across development was performed using a oneway ANOVA (Fig. 1) . Differences were considered statistically significant at P , 0.05. Single statistical comparison between two groups was performed using a two-tailed Student's t-test (for example, comparison of measures in Pet1 2/2 and wild-type littermates or sMaoa 2/2 and wild-type littermates at a single age or in utero PCPA-versus vehicle-injected mice; see Fig. 3 and Supplementary  Tables 1 and 2 ). In vitro 5-HT synthesis assays. Pregnant CD-1 mice were anaesthetized by an intraperitoneal injection of 0.2 ml pentobarbital and perfused through the left ventricle with 100 ml of phosphate buffered saline (PBS). The uterus was immediately dissected and the resulting embryos were placed on ice in PBS. The placenta, forebrain and hindbrain were removed and kept on ice in 1.5 ml eppendorf tubes. The collected tissue was homogenized in 3 volumes of 0.05 M Tris buffer, pH 7.5, containing 1 mM dithiothreitol and 1 mM EGTA. Homogenates were centrifuged at 29,000g for 15 min at 4 uC and the supernatants were placed on ice; tryptophan hydroxylase assays were performed as previously described 31 . Briefly, 70 mg of protein from the supernatant was added to tubes containing 100 ml of: 0.05 M Tris buffer, pH 7.5, 1 mM EGTA, 15 mg catalase, 250 mM L-tryptophan, and 50 mM tetrahydrobiopterin (BH4; a cofactor required for TPH1 and TPH2 activity 32 ). Reactions were performed for 10 and 30 min at 37 uC and stopped by flash freezing in liquid nitrogen. L-tryptophan metabolism was determined by measuring 5-hydroxytryptophan (5-HTP), 5-hydroxytyptamine (5-HT), and 5-hydroxyindoleacetic acid (5-HIAA) using HPLC with electrochemical detection (see above). Protein concentrations were determined using a DC protein assay (Bio-Rad). In vitro MAO-A activity measures. MAO-A activity was determined by incubating forebrain and hindbrain homogenates with [ 14 C]-5-HT (1 mM) at 37 uC for 20 min. At the end of the incubation, the products were extracted and the radioactivity determined as described previously 33 . Immunohistochemistry. Brain sections were processed for immunohistochemistry using the following primary antibodies: anti-5-HT (rabbit, 1:1,000; goat, 1:1,000, Sigma), anti-NetrinG1a (goat, 1:250, RnD), anti-SERT (rabbit, 1:200, Sigma), anti-5-HTP (rabbit, 1:1,500; ImmunoStar) and anti-AADC (rabbit, 1:500, Abcam). The secondary antibodies (Jackson ImmunoResearch) were: Cy2-or Cy3-conjugated donkey anti-rabbit IgG (1:800), rhodamin-X conjugated donkey anti-goat (1:200) and biotin-conjugated anti-rabbit (1:1,000). 20 mm brain sections were permeabilized, and pre-incubated with blocking solution (0.1% Triton X-100, 2% fetal bovine serum) in PBS for 2 h and then incubated overnight with a primary antibody diluted in the same blocking solution at 4 uC. Sections were washed with PBS 1 0.1% Triton X-100 and incubated with appropriate secondary antibodies diluted in same blocking solutions for a minimum of 2 h at room temperature (22-25 uC) . Sections were then washed with PBS 1 0.1% Triton X-100 and mounted using a fluorescence anti-fade medium (Prolong Gold, Vector Laboratories). For non-fluorescent immunohistochemistry (for example, AADC staining), similar procedures were followed, except that the sections were incubated in methanol with 3% H 2 O 2 for 15 min to quench endogenous peroxidase activity. The reaction product was visualized using a Vector ABC Elite Kit (Vector Laboratories). Images were acquired on a Zeiss AxoplanII microscope coupled to an AxioCamHRc camera using Axiovision 4.1 software (Zeiss). For placental immunochemistry, 5 mm frozen sections were thawed for 15 min at room temperature then washed in a mixture of 13 PBS containing 0.1% Triton X-100 (PBS-T) for 15 min at room temperature to allow for membrane permeabilization. Endogenous HRP was quenched by incubating the slides in a solution of methanol containing 3% hydrogen peroxide for 15 min at room temperature. The slides were then incubated for 2 h in a solution of PBS-T containing 2% Fetal Bovine Serum (Blocking Solution). The slides were then incubated overnight with anti-MCT1 (MCT1 is a marker of syncytiotrophoblasts 34 ; chicken; 0.5 mgml 21 ) or anti-AADC or anti-TPH1 (rabbit; 1:500) overnight at room temperature. Slides were then washed 3 3 10 min in PBS-T and incubated with appropriate secondary antibodies (biotin-conjugated anti-chicken; 1:1,000 or biotin-conjugated anti-rabbit; 1:1,000; Jackson ImmunoResearch) for 2 h at room temperature. After 6 3 5 min washes, slides were processed for HRP visualization as described above.
In utero inhibition of placental TPH1. Pregnant CD-1 mice were anaesthetized by an intraperitoneal injection of 0.5-0.7 ml of 10% Nembutal and uterine horns exposed as previously described 4 . Glass micropipettes were filled with a solution of 10 mM PCPA (4-Chloro-DL-phenylalanine; an inhibitor of TPH1 enzymatic activity 35 ) in PBS and 0.1% fast green dye (FCF; Sigma). FCF was used to monitor visually the diffusion of solution into the fetal villi of the placenta. 2-5 ml were injected through the uterine wall into the labyrinth region in half of the placentas (n 5 4-6) for each pregnant mouse (n 5 3); remaining placentas were injected with vehicle only. After 30 min, the dam was killed and placentas and corresponding forebrains and hindbrains collected and quickly frozen in liquid N 2 . Samples were then processed for HPLC analysis as described above. Ex vivo dual perfusion of the mouse placenta. A single placenta with uterine and umbilical arteries and veins attached was harvested from a pregnant CD-1 mouse at E17.5 in warm PBS. The placenta was rapidly transferred to a thermostated tissue culture chamber (60 mm diameter, Warner Instruments) to which warm (37 uC) and oxygenated (95% O 2 , 5% CO 2 ) PBS solution was constantly provided. Using a dissection microscope, micro-catheters were carefully attached to the uterine artery on the maternal side and umbilical artery and vein on the fetal side of the placenta. The uterine artery at E17.5 (internal diameter is approximately 150 mm) was cannulated using a 150 mm outside diameter polyethylene microcatheter. Micro-catheters were kept solidly attached to the arteries or veins using micro-clamps (F.S.T.) and suture. The other end of the uterine artery microcatheter was connected to an 8-channel micro-manifold (Automate Scientific); each channel's polyethylene tubing was then connected to an individual fastswitching valve (1.5 ms response time; Automate Scientific); the artificial maternal solution (warm oxygenated PBS) was delivered to each individual channel through a pressurized cylinder connected to each valve. An electronic valve controller enabled timed sequential switching of maternal solutions. The input pressure was calibrated to allow a maximal flow rate of 10-20 mlmin 21 through the uterine artery micro-catheter. On the fetal side, the umbilical artery and vein were similarly cannulated; for E17.5 placentas polyethylene tubing with 100 mm internal diameter was used. The other end of the umbilical artery micro-catheter was directly connected to a 5 ml syringe containing the artificial fetal solution (PBS with 0.01% fast green dye FCF, Sigma) and mounted on a precision, computercontrolled syringe pump (Braintree Scientific); the infusion flow rate was set at 6 mlmin 21 . For fetal eluate collection, the umbilical vein was cannulated to 100 mm internal diameter polyethylene tubing; this tubing was then connected to a specially modified SmartSquirt system (Automate Scientific) which consisted of a micromanifold connected to eight independent 3-ml reservoirs in which a controlled negative pressure (215 PSI) was individually applied. The integrated fast-switching valves system allowed the application of negative pressure to each reservoir LETTER RESEARCH independently and sequentially, thus allowing individual fraction collection over time. The addition of fast green dye to the fetal perfusate allowed monitoring for any leak through and around the placenta during the perfusion.
